English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  PET/MR in dementia and other neurodegenerative diseases

Barthel, H., Schroeter, M. L., Hoffmann, K.-T., & Sabri, O. (2015). PET/MR in dementia and other neurodegenerative diseases. Seminars in Nuclear Medicine, 45(3), 224-233. doi:10.1053/j.semnuclmed.2014.12.003.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0029-7F80-B Version Permalink: http://hdl.handle.net/21.11116/0000-0003-79DF-B
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Barthel, Henryk1, Author
Schroeter, Matthias L.2, 3, Author              
Hoffmann, Karl-Titus4, Author
Sabri, Osama1, 3, Author
Affiliations:
1Department of Nuclear Medicine, University of Leipzig, Germany, ou_persistent22              
2Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, Leipzig, DE, ou_634549              
3Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany, ou_persistent22              
4Department of Neuroradiology, University of Leipzig, Germany, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: The spectrum of neurodegenerative diseases covers the dementias, parkinsonian syndromes, Huntington disease, amyotrophic lateral sclerosis, and prion diseases. In these entities, brain MRI is often used in clinical routine to exclude other pathologies and to demonstrate specific atrophy patterns. [18F]FDG PET delivers early and sensitive readouts of neural tissue loss, and more specific PET tracers currently in use clinically target β-amyloid plaques or dopaminergic deficiency. The recent integration of PET into MR technology offers a new chance to improve early and differential diagnosis of many neurodegenerative diseases. Initial evidence in the literature is available to support this notion. New emerging PET tracers, such as tracers that bind to tau or α-synuclein aggregates, as well as MR techniques, like diffusion-tensor imaging, resting-state functional MRI, and arterial spin labeling, have the potential to broaden the diagnostic capabilities of combined PET/MRI to image dementias, Parkinson disease, and other neurodegenerative diseases. The ultimate goal is to establish combined PET/MRI as a first-line imaging technique to provide, in a one-stop-shop fashion with improved patient comfort, all biomarker information required to increase diagnostic confidence toward specific diagnoses. The technical challenge of accurate PET data attenuation correction within PET/MRI systems needs yet to be solved. Apart from the projected clinical routine applications, future research would need to answer the questions of whether combined brain PET/MRI is able to improve basic research of neurodegenerative diseases and antineurodegeneration drug testing.

Details

show
hide
Language(s): eng - English
 Dates: 2015-04-022015-05
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.1053/j.semnuclmed.2014.12.003
PMID: 25841277
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Seminars in Nuclear Medicine
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: New York, NY, USA : Elsevier
Pages: - Volume / Issue: 45 (3) Sequence Number: - Start / End Page: 224 - 233 Identifier: ISSN: 0001-2998
CoNE: /journals/resource/0001-2998